Clinical Trials on Endometrial Squamous Cell Carcinoma

Total 12640 results

Gynecologic Oncology Group
National Cancer Institute (NCI)

Completed

Dalantercept in Treating Patients With Recurrent or Persistent Endometrial Cancer

Recurrent Uterine Corpus Carcinoma | Endometrial Clear Cell Adenocarcinoma | Endometrial Serous Adenocarcinoma | Endometrial Undifferentiated Carcinoma | Endometrial Adenocarcinoma | Endometrial Transitional Cell Carcinoma | Endometrial Mucinous Adenocarcinoma | Endometrial Mixed Adenocarcinoma | Endometrial...

United States
Gynecologic Oncology Group
National Cancer Institute (NCI)

Completed

Brivanib Alaninate in Treating Patients With Recurrent or Persistent Endometrial Cancer

Recurrent Uterine Corpus Carcinoma | Endometrial Clear Cell Adenocarcinoma | Endometrial Serous Adenocarcinoma | Endometrial Undifferentiated Carcinoma | Endometrial Adenocarcinoma | Endometrial Transitional Cell Carcinoma | Endometrial Mucinous Adenocarcinoma | Endometrial Mixed Adenocarcinoma | Endometrial...

United States
Centre Hospitalier Universitaire de Nice

Completed

In Vivo Damage Induced bu UV in the Epidermis of the Scalp

Squamous Cell Carcinomas

France
Gynecologic Oncology Group
National Cancer Institute (NCI)

Completed

Nintedanib in Treating Patients With Recurrent or Persistent Endometrial Cancer

Recurrent Uterine Corpus Carcinoma | Endometrial Clear Cell Adenocarcinoma | Endometrial Serous Adenocarcinoma | Endometrial Undifferentiated Carcinoma | Endometrial Adenocarcinoma | Endometrial Transitional Cell Carcinoma | Endometrial Mucinous Adenocarcinoma | Endometrial Squamous Cell Carcinoma | Malignant Uterine Corpus Mixed Epithelial and Mesenchymal Neoplasm

United States
Peking University Third Hospital

Recruiting

RISI in the Treatment of Recurrent Metastatic SCC of Thoracic Inlet Lymph Nodes

Squamous Cell Carcinomas | Brachytherapy

China
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Recruiting

Tislelizumab Combined With Chemotherapy Followed by Surgery Versus Up-front Surgery in Resectable Head and Neck Squamous Cell Carcinoma (REDUCTION-I)

Head and Neck Squamous Cell Carcinomas

China
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Recruiting

Neoadjuvant Tislelizumab in Combination With Dasatinib and Quercetin in Resectable HNSCC (COIS-01)

Head and Neck Squamous Cell Carcinomas

China
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Recruiting

A Study of Toripalimab as Consolidation Therapy After Postoperative Chemoradiotherapy in HNSCC

Head and Neck Squamous Cell Carcinomas

China
Hospital of Stomatology, Wuhan University

Recruiting

The Combination of Adebrelimab and TP Regimen for Neoadjuvant Therapy in Patients With Stage IVB Oral Squamous Cell Carcinoma

Clinical IVb Stage Oral Squamous Cell Carcinomas Patients

China
Xiang Lu

Recruiting

Neoadjuvant Tislelizumab Plus Chemotherapy for Resectable Locally-advanced Head and Neck Squamous Cell Carcinoma

Head and Neck Squamous Cell Carcinomas | Resectable Head and Neck Squamous-cell Carcinoma

China
Hi-Q Marine Biotech International, Ltd.

Recruiting

A Randomized, Double-blind Study to Evaluate the Clinical Effect and Safety of Fucoidan in Patients With Squamous Cell Carcinomas of the Head and Neck

Squamous Cell Carcinomas of the Head and Neck

Taiwan
Rennes University Hospital

Completed

One-step Nucleic Acid Amplification for Detecting Lymph Node Metastasis of Head and Neck Squamous Cell Carcinoma (OSNA-ORL)

cN0 Oral Squamous Cell Carcinomas

France
Assistance Publique - Hôpitaux de Paris
National Cancer Institute (NCI); Canceropôle Ile de France

Completed

Comprehensive Geriatric Assessment and Head and Neck Elderly Cancer Patients (EGéSOR)

Head and Neck Squamous Cell Carcinomas (HNSCCs)

France
Sun Yat-sen University

Not yet recruiting

Myeloprotection With Trilaciclib in Pan-cancer Population

Cervical Cancer | Breast Cancer | Non-Small Cell Lung Cancer | Endometrial Cancer | Head And Neck Squamous Cell Carcinomas

China
British Columbia Cancer Agency

Withdrawn

Dose Escalation Trial of Neoadjuvant Sorafenib and Concurrent Sorafenib, Cisplatin and Radiation in Locally Advanced Squamous Cell Carcinomas of the Head and Neck (SCCHN)

Locally Advanced Squamous Cell Carcinomas of the Head and Neck (SCCHN)

Canada
National Cancer Institute (NCI)

Terminated

Capecitabine and Vorinostat in Treating Patients With Recurrent and/or Metastatic Head and Neck Cancer

Recurrent Hypopharyngeal Squamous Cell Carcinoma | Recurrent Laryngeal Squamous Cell Carcinoma | Recurrent Oral Cavity Squamous Cell Carcinoma | Recurrent Oropharyngeal Squamous Cell Carcinoma | Stage IVA Oral Cavity Squamous Cell Carcinoma | Stage IVA Laryngeal Squamous Cell Carcinoma | Stage... and other conditions

Canada, United States
Wake Forest University Health Sciences
National Cancer Institute (NCI)

Completed

Prepare to Care, A Supported Self-Management Intervention for Head and Neck Cancer CaregiversHead and Neck Cancer

Recurrent Head and Neck Squamous Cell Carcinoma | Recurrent Hypopharyngeal Squamous Cell Carcinoma | Recurrent Laryngeal Squamous Cell Carcinoma | Caregiver | Salivary Gland Squamous Cell Carcinoma | Malignant Head and Neck Neoplasm | Recurrent Lip and Oral Cavity Squamous Cell Carcinoma | Stage... and other conditions

United States
Sidney Kimmel Cancer Center at Thomas Jefferson...
Bristol-Myers Squibb

Completed

Nivolumab, Carboplatin, and Paclitaxel in Treating Patients With Stage III-IV Head and Neck Squamous Cell Carcinoma That Can Be Removed by Surgery

Stage IVA Oral Cavity Squamous Cell Carcinoma | Stage IV Hypopharyngeal Squamous Cell Carcinoma | Stage IVA Laryngeal Squamous Cell Carcinoma | Stage IVA Oropharyngeal Squamous Cell Carcinoma | Stage IVB Laryngeal Squamous Cell Carcinoma | Stage IVB Oropharyngeal Squamous Cell Carcinoma | Stage... and other conditions

United States
Emory University
Synta Pharmaceuticals Corp.

Terminated

Ganetespib Window of Opportunity Study in Head and Neck Cancers

Stage IVA Oral Cavity Squamous Cell Carcinoma | Stage IVA Laryngeal Squamous Cell Carcinoma | Stage IVA Oropharyngeal Squamous Cell Carcinoma | Stage I Hypopharyngeal Squamous Cell Carcinoma | Stage I Laryngeal Squamous Cell Carcinoma | Stage I Oropharyngeal Squamous Cell Carcinoma | Stage II... and other conditions

United States
Case Comprehensive Cancer Center
National Cancer Institute (NCI)

Terminated

Stereotactic Body Radiation Therapy in Treating Patients With High Risk Locally Advanced Head and Neck Cancer

Recurrent Hypopharyngeal Squamous Cell Carcinoma | Recurrent Laryngeal Squamous Cell Carcinoma | Recurrent Oral Cavity Squamous Cell Carcinoma | Recurrent Oropharyngeal Squamous Cell Carcinoma | Recurrent Nasopharyngeal Keratinizing Squamous Cell Carcinoma | Stage IVA Oral Cavity Squamous Cell... and other conditions

United States
NRG Oncology
National Cancer Institute (NCI)

Recruiting

Comparing High-Dose Cisplatin Every Three Weeks to Low-Dose Cisplatin Weekly When Combined With Radiation for Patients With Advanced Head and Neck Cancer

Advanced Head and Neck Squamous Cell Carcinoma | Squamous Cell Carcinoma of Unknown Primary | Advanced Hypopharyngeal Squamous Cell Carcinoma | Advanced Laryngeal Squamous Cell Carcinoma | Advanced Oropharyngeal Squamous Cell Carcinoma

United States, Canada
University Hospital, Montpellier
National Cancer Institute, France

Unknown

Circulating Tumor Cells as an Early Predictive head-and -Neck Squamous-cell Carcinoma (CIRCUTEC)

Metastatic Head-and-neck Squamous-cell Carcinoma

France
Maastricht University Medical Center

Recruiting

Decisional Conflicts, Health-related QoL and Satisfaction With Care in High-risk cSCC in the Head-neck Region

Quality of Life | Satisfaction, Patient | Squamous Cell Carcinoma of the Head and Neck | Squamous Cell Carcinoma of Head and Neck | Skin Cancer | Squamous Cell Carcinomas | Squamous Cell Carcinoma of the Skin | Cutaneous Squamous Cell Carcinoma of the Head and Neck | Cutaneous Squamous Cell Carcinoma | High-Risk Cancer

Netherlands
City of Hope Medical Center
National Cancer Institute (NCI); Genentech, Inc.

Recruiting

Radiotherapy in Combination With Atezolizumab in Locally Advanced Borderline Resectable or Unresectable Cutaneous SCC

Locally Advanced Skin Squamous Cell Carcinoma | Unresectable Skin Squamous Cell Carcinoma | Resectable Skin Squamous Cell Carcinoma

United States
GOG Foundation
National Cancer Institute (NCI)

Active, not recruiting

Radiation Therapy With or Without Cisplatin in Treating Patients With Recurrent Endometrial Cancer

Recurrent Endometrial Clear Cell Adenocarcinoma | Recurrent Endometrial Endometrioid Adenocarcinoma | Recurrent Endometrial Serous Adenocarcinoma | Recurrent Endometrial Undifferentiated Carcinoma | Recurrent Uterine Corpus Cancer | Endometrial Mucinous Adenocarcinoma | Endometrial Squamous Cell... and other conditions

United States, Canada
Baptist Health South Florida
Regeneron Pharmaceuticals

Withdrawn

Cemiplimab/Peg-Interferon-α in Advanced CSCC

Squamous Cell Carcinoma | Cutaneous Squamous Cell Carcinoma | Advanced Squamous Cell Carcinoma

United States
Gynecologic Oncology Group
National Cancer Institute (NCI)

Completed

Intraperitoneal Paclitaxel, Doxorubicin Hydrochloride, and Cisplatin in Treating Patients With Stage III-IV Endometrial Cancer

Recurrent Uterine Corpus Carcinoma | Endometrial Clear Cell Adenocarcinoma | Endometrial Serous Adenocarcinoma | Endometrial Undifferentiated Carcinoma | Endometrial Adenosquamous Carcinoma | Endometrial Mixed Adenocarcinoma | Stage IIIA Uterine Corpus Cancer | Stage IIIC Uterine Corpus Cancer | Stage... and other conditions

United States
H. Lee Moffitt Cancer Center and Research Institute
AstraZeneca; Brooklyn ImmunoTherapeutics, LLC

Active, not recruiting

IRX-2 Regimen and Durvalumab, for Incurable H&N Squamous Cell Carcinoma

Squamous Cell Carcinoma of the Head and Neck | Oropharynx Squamous Cell Carcinoma | Squamous Cell Carcinoma | Oral Cavity Squamous Cell Carcinoma | Metastatic Squamous Cell Carcinoma | Hypopharynx Squamous Cell Carcinoma | Paranasal Sinus Squamous Cell Carcinoma | Larynx Squamous Cell Carcinoma

United States
National Cancer Institute (NCI)

Completed

Temsirolimus in Treating Patients With Metastatic or Locally Advanced Recurrent Endometrial Cancer

Recurrent Endometrial Carcinoma | Endometrial Adenocarcinoma | Endometrial Clear Cell Carcinoma | Endometrial Papillary Serous Carcinoma | Stage IIIA Endometrial Carcinoma | Stage IIIB Endometrial Carcinoma | Stage IIIC Endometrial Carcinoma | Stage IVA Endometrial Carcinoma | Stage IVB Endometrial... and other conditions

Canada
UNC Lineberger Comprehensive Cancer Center
Mayo Clinic; National Institute of Dental and Craniofacial Research (NIDCR)

Recruiting

Prospective Observational Study to Validate Circulating HPVDNA and Prognostic Genomic Biomarkers in HPV-associated OPSCC

Carcinoma, Squamous Cell | Head and Neck Squamous Cell Carcinoma | Oropharyngeal Squamous Cell Carcinoma | Oropharynx Squamous Cell Carcinoma

United States
Rutgers, The State University of New Jersey
National Cancer Institute (NCI)

Completed

Talimogene Laherparepvec and Panitumumab for the Treatment of Locally Advanced or Metastatic Squamous Cell Carcinoma of the Skin

Metastatic Skin Squamous Cell Carcinoma | Recurrent Skin Squamous Cell Carcinoma | Locally Advanced Skin Squamous Cell Carcinoma

United States
Nanjing Tongren Hospital

Unknown

CTC Detection Rate in SCCHN With a in Vivo Device

Squamous Cell Carcinoma of the Head and Neck | Circulating Tumor Cell

China
Onconova Therapeutics, Inc.

Completed

Oral Rigosertib for Squamous Cell Carcinoma

Head and Neck Squamous Cell Carcinoma | Esophageal Squamous Cell Carcinoma | Anal Squamous Cell Carcinoma | Cervical Squamous Cell Carcinoma | Skin Squamous Cell Carcinoma | Lung Squamous Cell Carcinoma | Penile Squamous Cell Carcinoma

United States
Biotech Pharmaceutical Co., Ltd.

Unknown

Nimotuzumab in Combined With Paclitaxel and Cisplatin for Treatment of Metastatic Esophageal Squamous Cell Carcinoma

Esophageal Squamous Cell Carcinomas

China
Emory University
National Cancer Institute (NCI); National Institutes of Health (NIH); Exelixis

Active, not recruiting

Pembrolizumab & Cabozantinib in Patients With Head and Neck Squamous Cell Cancer

Recurrent Head and Neck Squamous Cell Carcinoma | Recurrent Hypopharyngeal Squamous Cell Carcinoma | Recurrent Laryngeal Squamous Cell Carcinoma | Recurrent Oral Cavity Squamous Cell Carcinoma | Recurrent Oropharyngeal Squamous Cell Carcinoma | Stage IV Hypopharyngeal Squamous Cell Carcinoma... and other conditions

United States
Replimune Inc.
Regeneron Pharmaceuticals

Active, not recruiting

Study Evaluating Cemiplimab Alone and Combined With RP1 in Treating Advanced Squamous Skin Cancer (CERPASS)

Cutaneous Squamous Cell Carcinoma | Advanced Cutaneous Squamous Cell Carcinoma | Metastatic Cutaneous Squamous Cell Carcinoma

Spain, United States, France, Australia, Germany, Canada, Greece, Bulgaria, Italy, Poland
Shanghai Chest Hospital

Not yet recruiting

Salvage Immunotherapy and Chemotherapy in Esophageal Squamous Cell Carcinoma Patients Nonresponding to Initial Neoadjuvant Chemoradiotherapy (SINCERE)

Esophageal Squamous Cell Carcinomas
Fuzhou General Hospital

Recruiting

Camrelizumab Combined With Radiotherapy for Adjuvant Treatment of Esophageal Squamous Cell Carcinoma After Surgery

Esophageal Squamous Cell Carcinomas

China
Hyunseok Kang, MD
NeoImmuneTech

Recruiting

NT-I7 for the Treatment of Recurrent Squamous Cell Carcinoma of Head and Neck Undergoing Surgery

Recurrent Head and Neck Squamous Cell Carcinoma | Recurrent Hypopharyngeal Squamous Cell Carcinoma | Recurrent Laryngeal Squamous Cell Carcinoma | Recurrent Oral Cavity Squamous Cell Carcinoma | Recurrent Oropharyngeal Squamous Cell Carcinoma | Resectable Oropharyngeal Squamous Cell Carcinoma

United States
Regeneron Pharmaceuticals
Sanofi

Recruiting

Intralesional Cemiplimab for Adult Patients With Cutaneous Squamous Cell Carcinoma or Basal Cell Carcinoma

Basal Cell Carcinoma | Cutaneous Squamous Cell Carcinoma

United States
Rakuten Medical, Inc.

Active, not recruiting

An Open-label Study Using ASP-1929 Photoimmunotherapy in Combination With Anti-PD1 Therapy in EGFR Expressing Advanced Solid Tumors

Recurrent Head and Neck Squamous Cell Carcinoma | Metastatic Head-and-neck Squamous-cell Carcinoma | Metastatic Cutaneous Squamous Cell Carcinoma | Locally Advanced Cutaneous Squamous Cell Carcinoma

United States
Second Xiangya Hospital of Central South University
Shanghai OrigiMed Co., Ltd.

Recruiting

The Role of ctDNA Testing Plus AI-based Pathology in Resectable LSCC

Lung Squamous Cell Carcinoma

China
The Netherlands Cancer Institute

Recruiting

Neo-adjuvant Nivolumab or Nivolumab With Ipilimumab in Advanced Cutaneous Squamous Cell Carcinoma Prior to Surgery (MATISSE)

Cutaneous Squamous Cell Carcinoma

Netherlands
University of Michigan Rogel Cancer Center
Bristol-Myers Squibb

Active, not recruiting

Radiotherapy, Carboplatin/Paclitaxel and Nivolumab for High Risk HPV-related Head and Neck Cancer

Oropharynx Squamous Cell Carcinoma

United States
Queen Mary University of London

Active, not recruiting

Cutaneous Squamous Cell Carcinoma Staging Study

Cutaneous Squamous Cell Carcinoma

United Kingdom
Fondazione Melanoma Onlus

Active, not recruiting

Neoadjuvant Plus Adjuvant Treatment With Cemiplimab in Cutaneaous Squamous Cell Carcinoma

Cutaneous Squamous Cell Carcinoma

Italy
H. Lee Moffitt Cancer Center and Research Institute

Withdrawn

Biological Outcomes of Pramlintide in Resectable Cutaneous Squamous Cell Carcinoma: A Pilot Study

Cutaneous Squamous Cell Carcinoma

United States
CMR Surgical Ltd
Liverpool University Hospitals NHS Foundation Trust; Sintesi Research S.r.l.

Recruiting

Prospective Clinical Study to Assess the Safety and Efficacy of Versius, in Transoral Robotic Surgery

Squamous Cell Carcinoma of the Oropharynx | Squamous Cell Carcinoma, Unknown Primary

United Kingdom
National Cancer Institute (NCI)

Completed

Soy Isoflavones in Preventing Head and Neck Cancer Recurrence in Patients With Stage I-IV Head and Neck Cancer Undergoing Surgery

Recurrent Hypopharyngeal Squamous Cell Carcinoma | Recurrent Laryngeal Squamous Cell Carcinoma | Recurrent Oropharyngeal Squamous Cell Carcinoma | Recurrent Lip and Oral Cavity Squamous Cell Carcinoma | Recurrent Laryngeal Verrucous Carcinoma | Recurrent Oral Cavity Verrucous Carcinoma | Tongue... and other conditions

United States
Wake Forest University Health Sciences
National Cancer Institute (NCI)

Completed

Durvalumab Before Surgery in Treating Patients With Oral Cavity or Oropharynx Cancer

Human Papillomavirus Infection | Stage IVA Oral Cavity Squamous Cell Carcinoma | Stage IVA Oropharyngeal Squamous Cell Carcinoma | Stage IVB Oropharyngeal Squamous Cell Carcinoma | Stage IVC Oropharyngeal Squamous Cell Carcinoma | Stage I Oropharyngeal Squamous Cell Carcinoma | Stage II Oropharyngeal... and other conditions

United States

Clinical Trials on Endometrial Squamous Cell Carcinoma

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Macedonia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations